Data from the phase 1b MonumenTAL-2 trial support pomalidomide plus talquetamab as a promising treatment option in relapsed/refractory multiple myeloma, says Jeffrey Matous, MD.
Talquetamab-tgvs (Talvey) plus pomalidomide (Pomalyst) may be the “best” pomalidomide-based combination for treating patients with relapsed/refractory multiple myeloma based on a high rate of durable responses in a small cohort of patients in the phase 1b MonumenTAL-2 trial, Jeffrey Matous, MD said.
In an interview with CancerNetwork® during the 2023 American Society of Hematology (ASH) Annual Meeting and Exposition, Matous, a member physician at the Colorado Blood Cancer Institute and part of the Plasma Cell Diseases Group, as well as a member of the Sarah Cannon Research Institute Myeloma Executive Committee, stated that the response benefit achieved with the pomalidomide combination in the MonumenTAL-2 trial extended to those with high-risk or extramedullary disease.
The overall response rate (ORR) was 93.8% (n = 15/16) when pomalidomide was administered at 0.4 mg/kg every week and 84.2% (n = 16/19) when the drug was given at a dose of 0.8 mg/kg every 2 weeks in combination with talquetamab. Additionally, it was reported that the median duration of response (DOR) was not reached (NR; 95% CI, 12.0-NR) in the 0.4 mg/kg weekly cohort and the 0.8 mg/kg every 2 weeks cohort (95% CI, 7.4-NR). The 9-month DOR rates were 100.0% (95% CI, 100.0%-100.0%) and 83.9% (95% CI, 49.4%-95.7%) in each respective cohort.
Transcript:
In this group of patients who had a medium of 3 prior therapies, the overall response rate was [approximately] 90%. Many of those responses were very deep; they were complete responses.The responses occurred quickly at a median of just between 1 and 2 months, and most of them were very durable. There was a subset of patients who had either high-risk disease or even extramedullary disease, and we saw responses in those patients as well. [There was a] very encouraging therapeutic response with this combination—one that I personally think is probably the best pair we’ve seen with pomalidomide yet in terms of treating relapsed/refractory multiple myeloma.
If you look at combinations with pomalidomide and other agents in the relapsed/refractory myeloma setting, this is by far the most potent one that we’ve seen. This [combination] has great promise. I can just speak to the patients at our institution who have participated in this research trial, most of whom have ongoing stringent complete responses over a year into therapy. It’s very encouraging.
Matous J, Biran N, Perrot A, et al. Talquetamab + pomalidomide in patients with relapsed/refractory multiple myeloma: safety and preliminary efficacy results from the phase 1b MonumenTAL-2 study. Blood. 2023;142(suppl 1):1014. doi:10.1182/blood-2023-187706
Early Intervention, Regular Assessment Can Grasp Symptom Course for Head and Neck Cancer Therapy
April 28th 2024Nurses must increase the frequency of their assessments for early intervention of patients who undergo treatment for their head and neck cancer, in an effort to truly individualized care.
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.